JP2018529739A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529739A5
JP2018529739A5 JP2018517345A JP2018517345A JP2018529739A5 JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5 JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5
Authority
JP
Japan
Prior art keywords
alkylene
aryl
cycloalkyl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517345A
Other languages
English (en)
Japanese (ja)
Other versions
JP6896715B2 (ja
JP2018529739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054657 external-priority patent/WO2017059191A1/en
Publication of JP2018529739A publication Critical patent/JP2018529739A/ja
Publication of JP2018529739A5 publication Critical patent/JP2018529739A5/ja
Application granted granted Critical
Publication of JP6896715B2 publication Critical patent/JP6896715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517345A 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体 Active JP6896715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235191P 2015-09-30 2015-09-30
US62/235,191 2015-09-30
PCT/US2016/054657 WO2017059191A1 (en) 2015-09-30 2016-09-30 Heteroaryl derivatives as sepiapterin reductase inhibitors

Publications (3)

Publication Number Publication Date
JP2018529739A JP2018529739A (ja) 2018-10-11
JP2018529739A5 true JP2018529739A5 (https=) 2019-11-14
JP6896715B2 JP6896715B2 (ja) 2021-06-30

Family

ID=57133442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517345A Active JP6896715B2 (ja) 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体

Country Status (7)

Country Link
US (1) US9963462B2 (https=)
EP (1) EP3356345B1 (https=)
JP (1) JP6896715B2 (https=)
CA (1) CA3038280A1 (https=)
DK (1) DK3356345T3 (https=)
ES (1) ES2969565T3 (https=)
WO (1) WO2017059191A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CN107312011A (zh) * 2017-06-29 2017-11-03 上海药明康德新药开发有限公司 外消旋‑7‑叔丁氧基羰基‑1‑氧亚基‑2,7‑二氮杂螺壬烷‑4‑羧酸的合成方法
CN107817307B (zh) * 2017-11-01 2020-12-25 重庆华邦制药有限公司 Hplc法分离测定帕司烟肼及其相关杂质的方法
WO2019145174A1 (en) 2018-01-23 2019-08-01 Basf Se Preparation of optionally substituted 5-substituted pyridine
CN111630034B (zh) 2018-01-23 2026-01-16 巴斯夫欧洲公司 吡啶衍生物的溴化
CN111630042A (zh) 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
WO2019145178A1 (en) 2018-01-23 2019-08-01 Basf Se Preparation of optionally substituted dihydroisoquinolines
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
TWI803696B (zh) * 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
US11401273B2 (en) 2018-11-20 2022-08-02 Piramal Pharma Limited Asymmetric synthesis of Azaspiro compounds
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
RS65302B1 (sr) * 2019-07-17 2024-04-30 Cytokinetics Inc Oralne formulacije inhibitora srčanog sarkomera
US20240139190A1 (en) * 2019-10-18 2024-05-02 The Board Of Regents Of The University Of Texas System Novel antiparasitic compounds and methods
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物
JP2021123539A (ja) * 2020-02-03 2021-08-30 キッセイ薬品工業株式会社 ピロロピリミジノン化合物
JP7611900B2 (ja) * 2020-04-14 2025-01-10 日産化学株式会社 縮合複素環化合物
CN111393366B (zh) * 2020-06-05 2020-09-01 北京华氏开元医药科技有限公司 四氢异喹啉类衍生物、制备方法、药物组合物及应用
EP4185381A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Thiophene hsd17b13 inhibitors and uses thereof
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2021377248B2 (en) 2020-11-13 2025-12-18 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
CN113072420B (zh) * 2021-02-23 2022-05-20 中山大学 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法
CN116490498B (zh) * 2021-03-19 2025-09-02 南京迈晟科技有限责任公司 嘧啶并环类化合物及其用于制备治疗疼痛、脊髓损伤药物中的用途
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Kdm5阻害作用を有する化合物を含有する医薬組成物
IL315733A (en) 2022-04-08 2024-11-01 SHY Therapeutics LLC Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases
CN118184657A (zh) * 2022-11-23 2024-06-14 成都先导药物开发股份有限公司 Parp7抑制剂及其制备方法和用途
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种(r)-4,4-二氟代吡咯烷-2-羧酸的制备方法
EP4731207A2 (en) * 2023-06-26 2026-04-29 Merck Sharp & Dohme LLC Inhibitors of human respiratory syncytial virus and metapneumovirus

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040047A (en) 1960-04-04 1962-06-19 Takeda Pharmaceutical 2-(pyrazol-1-yl)-pyrimidine derivatives
JPH04182636A (ja) 1990-11-19 1992-06-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
JPH05341428A (ja) 1992-06-10 1993-12-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
TW312694B (https=) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
HU228316B1 (en) 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Hcv 저해 바이-사이클릭 피리미딘
BRPI0608411A2 (pt) 2005-03-10 2009-12-29 Basf Ag uso de um composto, composto, processo para preparar compostos, agente, semente, e, processo para combater fungos nocivos fitopatogênicos
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
WO2008055709A1 (en) 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20110046137A1 (en) 2007-05-10 2011-02-24 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
HRP20151052T1 (xx) * 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
RU2528412C2 (ru) 2009-02-10 2014-09-20 Янссен Фармацевтика Нв Хиназолиноны как ингибиторы пролилгидроксилазы
US20120252791A1 (en) 2009-09-17 2012-10-04 Julian Blagg Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain
CA2777782C (en) * 2009-10-15 2016-06-28 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
WO2011088045A1 (en) 2010-01-12 2011-07-21 Ambit Biosciences Corporation Aurora kinase compounds and methods of their use
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
WO2013132253A1 (en) * 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
AR097631A1 (es) * 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos

Similar Documents

Publication Publication Date Title
JP2018529739A5 (https=)
JP2019502763A5 (https=)
JP2016515560A5 (https=)
JP2015514808A5 (https=)
JP2017509689A5 (https=)
JP2013529196A5 (https=)
JP2016514719A5 (https=)
JP2016530283A5 (https=)
JP2010526098A5 (https=)
JP2015537017A5 (https=)
JP2019524883A5 (https=)
JP2019512505A5 (https=)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2018524390A5 (https=)
JP2018529650A5 (https=)
JP2015503625A5 (https=)
JP2016506961A5 (https=)
JP2012524056A5 (https=)
JP2016540742A5 (https=)
JP2016525135A5 (https=)
AR081830A1 (es) Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos
JP2015531366A5 (https=)
JP2010522194A5 (https=)
JP2017506675A5 (https=)
JP2017517512A5 (https=)